Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Clobetasol Propionate

FDA-approved product (cream, topical), marketed as Byqlovi, Clobetasol Propionate, Clobetasol Propionate (Emollient) and 10 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Clobetasol Propionate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Psoriasis
  • Psoriasis vulgaris
  • Skin disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids, very potent (group iv)
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis35.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Clobetasol Propionate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Clobetasol Propionate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Topical Clobetasol Propionate for Inflammatory Hand Osteoarthritis

    NCT07812701 · start 2026-09

    Registered record
    Registry ID
    NCT07812701
    Conditions
    Hand Osteoarthritis
    Interventions
    Propionate de Clobétasol ( 0.05 %); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-09
    Completion
    2027-11
    Enrolment
    187

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHand Osteoarthritis
    InterventionPropionate de Clobétasol ( 0.05 %); Placebo
    PhasePhase 2
    Registry statusNot yet recruiting

  • The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery)

    NCT07276802 · start 2026-04-01

    Registered record
    Registry ID
    NCT07276802
    Conditions
    Post Cataract Surgery
    Interventions
    Triamcinolone (Optional); control group
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-04-01
    Completion
    2027-01-31
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost Cataract Surgery
    InterventionTriamcinolone (Optional); control group
    PhasePhase 4
    Registry statusNot yet recruiting

  • Comparison of the Efficacy of Clobetasol Propionate 0.05% Mouthwash, Photobiomodulation, and Their Combination in Managing of Oral Lesions in Patient With Pemphigus Vulgaris.

    NCT07641725 · start 2025-11-01

    Registered record
    Registry ID
    NCT07641725
    Conditions
    Oral Lesions in Patients With Pemphigus Vulgaris
    Interventions
    Clobetasol propionate 0.05% Mouthwash; diode laser for photobiomodulation; clobetasol propionate 0.05% mouthwash + photobiomodulation
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-11-01
    Completion
    2026-12-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOral Lesions in Patients With Pemphigus Vulgaris
    InterventionClobetasol propionate 0.05% Mouthwash; diode laser for photobiomodulation; clobetasol propionate 0.05% mouthwash + photobiomodulation
    PhaseNot applicable
    Registry statusRecruiting

  • Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

    NCT06504160 · start 2025-05-22

    Registered record
    Registry ID
    NCT06504160
    Conditions
    Atopic Dermatitis
    Interventions
    ShA9 Topical Gel; Hydrocortisone Ointment; Clobetasol Ointment; Fluocinonide Ointment; Placebo (Vehicle) Topical Gel; Triamcinolone Ointment
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2025-05-22
    Completion
    2027-02-05
    Enrolment
    86

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionShA9 Topical Gel; Hydrocortisone Ointment; Clobetasol Ointment; Fluocinonide Ointment +2 more
    PhasePhase 1
    Registry statusRecruiting

  • Screening for Adrenal Insufficiency During Dermocorticoid Reduction in Bullous Pemphigoid (BP)

    NCT06148090 · start 2024-01-04

    Registered record
    Registry ID
    NCT06148090
    Conditions
    Pemphigoid, Bullous; Adrenal Insufficiency
    Interventions
    clobetasol decreasing measurement
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2024-01-04
    Completion
    2026-01-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPemphigoid, Bullous; Adrenal Insufficiency
    Interventionclobetasol decreasing measurement
    PhaseNot applicable
    Registry statusUnknown

  • Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis

    NCT06042647 · start 2023-07-13

    Registered record
    Registry ID
    NCT06042647
    Conditions
    Psoriasis Vulgaris
    Interventions
    0.01% Halobetasol; 0.045% Tazarotene; 0.05% Clobetasol Propionate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2023-07-13
    Completion
    2023-11-13
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis Vulgaris
    Intervention0.01% Halobetasol; 0.045% Tazarotene; 0.05% Clobetasol Propionate
    PhasePhase 4
    Registry statusCompleted

  • Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population

    NCT05724446 · start 2022-12-12

    Registered record
    Registry ID
    NCT05724446
    Conditions
    Cataracts Infantile
    Interventions
    Clobetasol Propionate; Prednisolone acetate ophthalmic suspension, 1%
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2022-12-12
    Completion
    2025-12-31
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCataracts Infantile
    InterventionClobetasol Propionate; Prednisolone acetate ophthalmic suspension, 1%
    PhasePhase 3
    Registry statusRecruiting

  • Comparative Efficacy of Tacrolimus and Clobetasol Propionate in Alopecia Areata

    NCT05885269 · start 2022-11-01

    Registered record
    Registry ID
    NCT05885269
    Conditions
    Alopecia Areata
    Interventions
    Group A applied topical Clobetasol Propionate; Group B applied topical Tacrolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-11-01
    Completion
    2023-04-30
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlopecia Areata
    InterventionGroup A applied topical Clobetasol Propionate; Group B applied topical Tacrolimus
    PhasePhase 1
    Registry statusCompleted

  • Does Steroid Plus CO2 Laser Improve Lichen Sclerosus Symptoms Compared to Steroids Alone?

    NCT05243563 · start 2022-04-13

    Registered record
    Registry ID
    NCT05243563
    Conditions
    Vulvar Lichen Sclerosus
    Interventions
    MonaLisa Touch; Topical steroid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2022-04-13
    Completion
    2024-06-03
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVulvar Lichen Sclerosus
    InterventionMonaLisa Touch; Topical steroid
    PhasePhase 2 / Phase 3
    Registry statusTerminated

  • Phase I Study of GN-037 Cream for Psoriasis

    NCT05428202 · start 2022-03-28

    Registered record
    Registry ID
    NCT05428202
    Conditions
    Psoriasis
    Interventions
    GN037; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-03-28
    Completion
    2022-09-30
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionGN037; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Topical 1% Methotrexate Gel Versus Clobetasol Propionate in Patients With Psoriasis

    NCT06555497 · start 2022-01-01

    Registered record
    Registry ID
    NCT06555497
    Conditions
    Pilot Study; Psoriasis
    Interventions
    topical 1% methotrexate gel; clobetasol propionate 0.05% ointment
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2022-01-01
    Completion
    2023-12-31
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPilot Study; Psoriasis
    Interventiontopical 1% methotrexate gel; clobetasol propionate 0.05% ointment
    PhaseEarly phase 1
    Registry statusCompleted

  • Plasma Rich in Growth Factors (PRGF) for the Treatment of Lichen Sclerosus Atrophicus of the Vulva

    NCT05364515 · start 2021-12-23

    Registered record
    Registry ID
    NCT05364515
    Conditions
    Lichen Sclerosus of Vulva
    Interventions
    PRGF; Clobetasol Propionate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2021-12-23
    Completion
    2024-02-15
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLichen Sclerosus of Vulva
    InterventionPRGF; Clobetasol Propionate
    PhasePhase 3
    Registry statusWithdrawn

  • Impact of PDT and Topical Corticosteroids on Taste Perception and Salivary Oxidative Stress Markers in Patients With OLP

    NCT07536737 · start 2021-09-30

    Registered record
    Registry ID
    NCT07536737
    Conditions
    Oral Lichen Planus
    Interventions
    5-Amino Levulinic Acid; Clobetasol Propionate 0.05% Cream
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-09-30
    Completion
    2023-07-10
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOral Lichen Planus
    Intervention5-Amino Levulinic Acid; Clobetasol Propionate 0.05% Cream
    PhaseNot applicable
    Registry statusCompleted

  • Ointment Therapy and Prevention of Cannulation-Induced Superficial Phlebitis

    NCT04685031 · start 2021-02-01

    Registered record
    Registry ID
    NCT04685031
    Conditions
    Phlebitis
    Interventions
    Nitroglycerin ointment; Clobetasol Topical
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2021-02-01
    Completion
    2021-05-01
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPhlebitis
    InterventionNitroglycerin ointment; Clobetasol Topical
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis

    NCT03847389 · start 2019-09-09

    Registered record
    Registry ID
    NCT03847389
    Conditions
    Atopic Dermatitis
    Interventions
    Clobetasol propionate 0.05% Topical Oil
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2019-09-09
    Completion
    2020-07-28
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionClobetasol propionate 0.05% Topical Oil
    PhasePhase 1 / Phase 2
    Registry statusTerminated